The oncogene EWS-FLI1 encodes a chimeric transcription factor expressed in Ewing's sarcoma family tumors (ESFTs). EWS-FLI1 target gene expression is thought to drive ESFT pathogenesis and, therefore, inhibition of EWS-FLI1 activity holds high therapeutic promise. As the activity of many transcription factors is regulated by posttranslational modifications, we studied the presence of modifications on EWS-FLI1. The immuno-purified fusion-protein was recognized by an antibody specific for O-linked b-N-acetylglucosaminylation, and bound readily to a phosphoprotein-specific dye. Inhibition of Ser/Thrspecific phophatases increased EWS-FLI1 molecular weight and reduced its O-GlcNAc content, suggesting that phosphorylation and O-GlcNAcylation of EWS-FLI1 interact dynamically. By mutation analysis, O-GlcNAcylation was delineated to Ser/Thr residues of the amino-terminal EWS transcriptional-activation domain. Metabolic inhibition of the hexosamine biosynthetic pathway abrogated O-GlcNAcylation of EWS-FLI1 and interfered specifically with transcriptional activation of the EWS-FLI1 target Id2. These results suggest that drugs modulating glycosylation of EWS-FLI1 interfere functionally with its activity and might, therefore, constitute promising additions to the current ESFT chemotherapy.
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The translocation t(11;22)(q24;q12) fuses EWS and FLI1 genes resulting in a chimeric transcription factor that drives the pathogenesis of Ewing's sarcoma family tumors (ESFTs) (Kovar, 2005) . Modifications of EWS have been described at domains replaced by FLI1 in the fusion-protein. EWS is phosphorylated by protein kinase C within the IQ domain interfering with the RNA-binding activity of EWS (Deloulme et al., 1997) . The EWS C-terminal RGG boxes are dimethylated extensively, resulting in cytoplasmic retention of EWS (Araya et al., 2005) . Additionally, cell-cycle-dependent phosphorylation by Bruton's tyrosine kinase and glycosylation at unknown sites have been described for EWS (Guinamard et al., 1997; Matsuoka et al., 2002; Wells et al., 2002) . FLI1 is phosphorylated on serine residues by a calcium-dependent process, though modification sites have not been mapped (Zhang and Watson, 2005) . So far, nothing is known about PTMs of the oncogenic EWS-FLI1 protein. However, several lines of indirect evidence suggest that PTMs may be involved in specific EWS-FLI1 protein interactions. EWS and EWS-FLI1, despite sharing identical N-terminal domain (NTD) primary structure, differ in their ability to interact with the RNA Pol II subunit hsRPB7 (Petermann et al., 1998) and with antibodies directed to the N-terminus of the protein (Aryee et al., 2006) , which might be explained by distinct higher-order structure and specific PTMs of the fusion-protein. Also, although able to dimerize, EWS-FLI1 binds to DNA as a monomer (Spahn et al., 2003) , similar to EWS-WT1 in desmoplastic small-round-cell tumors, in which oligomerization and DNA binding of EWS-WT1 is regulated by phosphorylation (Kim et al., 1999) . Thus, it is likely that the function of EWS-fusionproteins is regulated by cellular signaling mechanisms. As the pharmacological targeting of nuclear-proteins is difficult, and knowledge about the type and physiological consequences of their PTMs may unravel upstream signaling molecules as potential therapeutic targets, we investigated PTMs of EWS-FLI1.
The EWS-FLI1 NTD (amino-acids 1-265) shares distant homology with the CTD (C-terminal domain) of eukaryotic RNA polymerase II (RNA Pol II.) (Delattre et al., 1992) . Heptapeptide repeats >50 of RNA Pol II CTD with the consensus YSPTSPS appear in EWS-FLI1 as 31 degenerate hexapeptide repeats with the consensus sequence SYGQQS. As the RNA Pol II CTD repeats are modified alternatively by phosphorylation on serines 2 and 5 of the repeats and, in the absence of phosphorylation, by O-GlcNAc on threonine and serine residues (Kelly et al., 1993) , we hypothesized that the EWS-NTD in EWS-FLI1 may be subject to a similar interplay between O-GlcNAc modification and phosphorylation.
EWS-FLI1 immunoprecipitated from the ESFT cell lines SK-N-MC ( Figure 1a ) and STA-ET-7.2 (not shown) was recognized readily by antibody RL2 which detects specifically single O-GlcNAc moieties on proteins (Snow et al., 1987) . Treatment of purified EWS-FLI1 protein with b-N-acetylglucosaminidase (GlcNAcase) abolished RL2 reactivity without affecting recognition by the FLI1 antibody 7.3 (Figure 1a) . To evaluate the proportion of EWS-FLI1 carrying O-GlcNAc modifications, immunoprecipitated EWS-FLI1 was subjected to a second round of immunoprecipitation with RL2 and, for control, unspecific antibody, and precipitates and supernatants were probed for EWS-FLI1 protein content. Almost no FLI1 antibody-reactive EWS-FLI1 remained in the supernatant after immunoprecipitation with RL2, whereas no EWS-FLI1 precipitated with the irrelevant antibody ( Figure 1b ). This result suggests that most EWS-FLI1 proteins in ESFT cells is O-GlcNAc modified. By contrast, intact FLI1 lacked reactivity with RL2, consistent with the modification being confined to the EWS-NTD ( Figure 1c ). Mutation of residues predicted to serve as the most probable O-GlcNAc acceptor sites by 'YinOYangmotif' search (Gupta and Brunak, 2002 ) (T185A, S202A, S239A, T244A), alone or in combination, did not alter reactivity of EWS-FLI1 with RL2 antibody (data not shown). However, combined conversion of Ser residues 40, 51, 69, 87, 111, 162, 168, 171 and of Thr residues 8, 22, 32, 48, 64, 79, 95 and 120, but not of all conserved glutamine residues in the EWS-NTD to alanine (Ng et al., 2007) , abolished completely reactivity with the O-GlcNAc-specific antibody RL2 (Figure 1d ). Variations in RL2 reactivity of the different EWS-NTD constructs as compared with full-length EWS-FLI1 result likely from structure-based differences of the proteins in accessibility for either RL2 antibody, GlcNAc transferase, or GlcNAcase, despite retaining full transcriptional activity (Ng et al., 2007) . These results suggest that O-GlcNAc modification of EWS-FLI1 is confined to serine-threonine residues within the EWS transactivation domain.
For RNA Pol II CTD, an intimate interplay of O-GlcNAc modification and phosphorylation has been shown. These two modifications occur on identical amino-acid residues and appear to be mutually exclusive and regulating each other (Hart et al., 2007) . Immunoprecipitated EWS-FLI1 was probed with Pro-Q Diamond phosphoprotein reagent on an SDS polyacrylamide-gel (Martin et al., 2003) . Figure 2a shows that EWS-FLI1 stained readily with this dye. The precipitating FLI1 antibody-band containing abundant protein and BSA stained negative with the phosphoprotein-dye indicating the specificity of the EWS-FLI1 signal. In addition, pre-treatment of immunoprecipitated EWS-FLI1 with alkaline phosphatase reduced staining with the phopsphoprotein dye ( Figure 2b ). This result identifies EWS-FLI1 as a phosphoprotein. Treatment of SK-N-MC cells with the serine-threonine phosphatase-inhibitor ocadaic acid increased EWS-FLI1 molecular weight and reduced reactivity with RL2 antibody, suggesting that forcing EWS-FLI1 phosphorylation reduces O-GlcNAc modification of EWS-FLI1 in line with a dynamic interplay between these two modifications on the EWS-FLI1 fusion-protein (Figure 2c ). The fact that both the higher and the lower molecular weight bands observed at 120 min of ocadaic-acid treatment still retain some reactivity with the RL2 antibody, indicates that hyperphosphorylation does not abrogate completely GlcNAc modification of EWS-FLI1. No effect on EWS-FLI1 mobility and RL2 reactivity was observed upon treating SK-N-MC cells with the tyrosine phosphatase-inihibitor orthovanadate (data not shown). These results suggest N-terminal O-GlcNAcylation of EWS-FLI1 communicating with Ser/Thr phosphorylation. b-N-acetylglucosamine is transferred to proteins by O-GlcNAc-transferase from UDP-GlcNAc, which is generated by the hexosamine biosynthetic pathway. Inhibition of glutamine:fructose-6-phosphate amidotransferase by the glutamine analog 6-diazo-5-oxo-Lnorleucine (DON) inhibits UDP-GlcNAc biosynthesis and reduces consequently protein O-GlcNAcylation, whereas inhibition of cellular O-GlcNAcase by GlcNAcstatin or Streptozotocin (STZ) stabilizes protein glycosylation. Treating SK-N-MC cells with DON abrogated EWS-FLI1 O-GlcNAcylation, whereas addition of increasing amounts of exogenous glucosamine restored EWS-FLI1 O-GlcNAcylation (Figure 3a) . In contrast, GlcNAcstatin and STZ increased moderately RL2 reactivity of the fusion-protein (Figures 3a and 4a) . Loss of O-GlcNAc modification was accompanied by a moderate decrease in overall protein levels of EWS-FLI1, which was restored by addition of exogenous glucosamine.
O-GlcNAcylation has been reported to play a role in the subcellular distribution of several transcription factors (Hart et al., 2007) . Therefore, we tested whether modulation of O-GlcNAcylation in ESFT cells with DON and STZ alters the subcellular localization of EWS-FLI1 (Figure 3b ). Nuclear PARP and cytoplasmic tubulin were used as surrogate markers for purity of subcellular fractions. In untreated cells, most EWS-FLI1 was found in the nuclear extract, but also the cytosolic fraction contained low amounts of the fusion-protein. DON treatment reduced the size and abundancy of EWS-FLI1, but did not change its proportional distribution to nuclear and cytosolic fractions. Conversely, STZ treatment increased slightly the EWS-FLI1 abundancy in both the nuclear and the cytoplasmic compartments. Consequently, the level of O-GlcNAcylation does not affect the subcellular localization of EWS-FLI1. Id2 and TGFbRII are activated directly and suppressed (Kovar, 2005) , respectively, by EWS-FLI1. Therefore, we asked whether O-GlcNAcylation affects the transcriptional activity of EWS-FLI1 by studying Id2 and TGFbRII expressions after DON-and STZtreatment of SK-N-MC cells. As an EWS-FLI1-negative control, we used the anaplastic large cell lymphoma cell line SU-DHL-2. In SK-N-MC cells, EWS-FLI1 protein levels were reduced to about 50% within 16 h of DON treatment, but remained unchanged by incubation with STZ ( Figure 4a ). During this period, DON led to an almost complete disappearance of O-GlcNAc modification on EWS-FLI1, whereas STZ increased RL2 reactivity by about 50% (Figure 1b ). Id2 and TGFbRII RNA expressions were measured by Q-PCR and were normalized to EWS-FLI1 protein levels to account for effects of inhibitor treatment on general gene expression. Interestingly, inhibition of O-GlcNAcylation in SK-N-MC cells resulted in an up to 10-fold decrease of Id2 expression within 16 h, whereas stabilization of O-GlcNAc modifications did not change Id2 RNA levels when compared with mock-treated cells (Figure 4c ). In contrast, TGFbRII suppression by EWS-FLI1 was not affected by either of the two inhibitors (Figure 4d ). However, in EWS-FLI1-negative SU-DHL-2 cells, both Id2 and TGFbRII levels remained unchanged largely. These results suggest that O-GlcNAcylation specifically supports the transcription-activating function of EWS-FLI1. This is the first report describing PTMs of the transcriptional-activation domain of EWS-FLI1 in ESFT and its functional consequences. We identified phosphorylation and O-linked glycosylation of this protein domain. In an earlier study (Wang et al., 1999) , it was found that inhibitors of N-linked glycosylation and of the mevalonate pathway impacts on the expression and function of EWS-FLI1. However, under their experimental conditions, the addition of single dynamic O-linked N-acetylglucosamine modification was not addressed and it was concluded that EWS-FLI1 is not a glycoprotein. PTMs had previously been shown to regulate the transcriptional activity of other EWS-fusion-proteins. For EWS-WT1, tyrosine-phosphorylation by the c-ABL kinase modulates dimerization and DNA-binding activity (Kim et al., 1999) . In addition, the protein tyrosine kinase v-SRC has been shown to interact with the EWS-NTD modulating the transcriptional activity of EWS-WT1 (Kim et al., 2000) . For both kinases, the sites of phosphorylation have not been mapped. In contrast, phosphorylation by protein kinase C modulating the transcriptional activity of rare EWS-ATF and EWS-ETS fusion-proteins that retain EWS exons 7 and 8, has been delineated to the aminoacid residue 266, which is not contained in the majority of EWS-FLI1 fusion-proteins (Ohlson et al., 2005) .
Here, we provide evidence that EWS-FLI1 is phosphorylated generally and O-GlcNAcylated in ESFT. As ocadaic acid, but not orthovanadate, affected the electrophoretic mobility and the interaction with O-GlcNAcylation of EWS-FLI1, the fusion-protein appears to be phosphorylated at Ser/Thr residues. The sites of phosphorylation overlap likely with those of O-GlcNAcylation. Our results map O-GlcNAc modifications to the EWS transcriptional-activation domain. The EWS-NTD is disordered intrinsically and overall protein structure, but not specific peptide sequences or individual repeats, has been reported to drive the transcriptional activity of EWS fusion-proteins (Ng et al., 2007) . For O-GlcNAcylation, no consensus sequence has been defined, and it is possible that due to the disordered structure of the EWS-NTD, this modification may occur at any serine or threonine residue dependent on the three-dimensional protein structure or by a stochastic process. Although the presence of multiple tyrosine residues distributed over the NTD was shown to be essential for the EWS transcriptional-activation function, our results using the glutamine:fructose-6-phosphate amidotransferase inhibitor DON suggest that glycosylation of serinethreonine residues might be equally important. We found that nearly all EWS-FLI1 is O-GlcNAcylated, suggesting this type of modification as an intrinsic characteristic of EWS-FLI1. The demonstration that inhibition of EWS-FLI1 glycosylation by DON impairs severely transcriptional EWS-FLI1 target gene activation, which is thought to mediate EWS-FLI1-driven oncogenesis, gives hope that this or related drugs may be of therapeutic value in ESFT. DON has been tested in several phase I/II clinical trials in adults and children since 1957 with dose-limiting toxicities (Lynch et al., 1982; Rahman et al., 1985; Sullivan et al., 1988) . Our finding, of a potentially specific DON-effect on EWS-FLI1 activity, suggests that DON might be a reasonable addition to polychemotherapy in children with ESFT.
